The members' enquiry service: frequently asked questions September 2001-August 2002 and an illustrative CEU response.
de Souza
Alison
A
Clinical Effectiveness Unit, Faculty of Family Planning and Reproductive Health Care, London, UK. ffp.ceu@abdn.ac.uk
Brechin
Susan
S
Penney
Gillian
G
D015519:Bone Density / Q000187:drug effects; D003258:Consumer Behavior; D003267:Contraception; D003271:Contraceptive Agents, Female / Q000009:adverse effects; D004958:Estradiol / Q000097:blood; D019317:Evidence-Based Medicine; D005193:Family Planning Services; D005260:Female; D006801:Humans; D007255:Information Services; D008297:Male; D017258:Medroxyprogesterone Acetate / Q000009:adverse effects; D034121:Reproductive Health Services; D012749:Sexually Transmitted Diseases / Q000175:diagnosis; D006113:United Kingdom
D003271:Contraceptive Agents, Female; D004958:Estradiol; D017258:Medroxyprogesterone Acetate